- Made Scientific has formed a collaboration with Basilard BioTech to accelerate the development of the Celletto™ gene delivery platform.
- The agreement includes validation and scale-up of the nanomechanical technology at Made Scientific’s GMP manufacturing site in Princeton, NJ.
Made Scientific, a US-based cell therapy contract development and manufacturing organisation (CDMO), has announced a strategic collaboration with Basilard BioTech. The partnership will focus on advancing Basilard BioTech’s nanomechanical gene delivery platform, Celletto™, designed to overcome limitations of both viral and conventional non-viral methods.
Celletto™ uses nanoneedles to transiently disrupt the cell membrane and transport genetic material directly into the nucleus. According to the release, the platform is engineered to deliver high gene transfer efficiency while maintaining cell viability, and offers scalability, reduced complexity, and lower costs compared with viral vector-based approaches.
Under the agreement, Basilard BioTech will utilise Made Scientific’s Center of Excellence for Process and Analytical Development and its GMP facility in Princeton, New Jersey. The companies will validate and scale Celletto™ across T cell and induced pluripotent stem cell (iPSC) processes, with future applications for other substrates.
Brynley Lee, Founder, President, and CEO of Basilard BioTech, said: “We look forward to collaborating with Made Scientific to demonstrate the transformative and disruptive potential of Celletto™.”
The collaboration is already underway with joint studies being executed. Initial data readouts are expected by the end of Q3 2025, followed by publication and presentation at upcoming industry conferences.
